Literature DB >> 17495133

The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations.

Hongbo Wang1, Bartosz Grzywacz, David Sukovich, Valarie McCullar, Qing Cao, Alisa B Lee, Bruce R Blazar, David N Cornfield, Jeffrey S Miller, Michael R Verneris.   

Abstract

Cyclosporin A (CSA) is commonly used to prevent graft-versus-host disease. The influence of CSA on T-cell function has been extensively investigated; however, the effect of CSA on natural killer (NK) cells is less understood. NK cells were cultured with IL-2 and IL-15 with and without CSA for 1 week. Compared with controls, CSA-treated cultures showed fewer CD56(+)CD16(+)KIR(+) NK cells and a reciprocal increase in CD56(+)CD16(-)KIR(-) cells. These changes were due mainly to a reduced proliferation of the CD56(dim) NK-cell subpopulation and a relative resistance of CD56(bright) NK cells to CSA. Following coculture with K562 targets, CSA-exposed NK cells differed from controls and lacked Ca(2+) oscillations, nuclear factor of activated T cells (NFAT) dephosphorylation, and NFAT nuclear translocation. NK cells cultured in CSA retained cytotoxicity against K562, Raji, and KIR ligand-expressing lymphoblastoid cells. NK cells cultured in CSA showed increases in NKp30 and reductions in NKp44 and NKG2D. Following IL-12 and IL-18 stimulation, CSA-treated NK cells showed more IFN-gamma-producing cells. Using in vitro NK-cell differentiation, progenitor cells gave rise to more CD56(+)KIR(-) NK cells in the presence of CSA than controls. Collectively, these studies show that CSA influences NK-cell function and phenotype, which may have important implications for graft-versus-leukemia effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17495133      PMCID: PMC1975839          DOI: 10.1182/blood-2006-10-048173

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

1.  Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

Authors:  T A Fehniger; M H Shah; M J Turner; J B VanDeusen; S P Whitman; M A Cooper; K Suzuki; M Wechser; F Goodsaid; M A Caligiuri
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

2.  Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors.

Authors:  Martin Bornhäuser; Rainer Schwerdtfeger; Hilmar Martin; Karl-Heinz Frank; Catrin Theuser; Gerhard Ehninger
Journal:  Blood       Date:  2004-04-01       Impact factor: 22.113

Review 3.  MHC class I molecules and KIRs in human history, health and survival.

Authors:  Peter Parham
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

Review 4.  Activating and inhibitory NK cell receptors.

Authors:  L L Lanier
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

5.  Tumor-induced apoptosis of human IL-2-activated NK cells: role of natural cytotoxicity receptors.

Authors:  Alessandro Poggi; Anna-Maria Massaro; Simone Negrini; Paola Contini; Maria Raffaella Zocchi
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

6.  In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine.

Authors:  G T Shin; A Khanna; R Ding; V K Sharma; M Lagman; B Li; M Suthanthiran
Journal:  Transplantation       Date:  1998-02-15       Impact factor: 4.939

7.  Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.

Authors:  L Ruggeri; M Capanni; M Casucci; I Volpi; A Tosti; K Perruccio; E Urbani; R S Negrin; M F Martelli; A Velardi
Journal:  Blood       Date:  1999-07-01       Impact factor: 22.113

8.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

Authors:  S Bauer; V Groh; J Wu; A Steinle; J H Phillips; L L Lanier; T Spies
Journal:  Science       Date:  1999-07-30       Impact factor: 47.728

9.  Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus.

Authors:  Tal I Arnon; Hagit Achdout; Ofer Levi; Gal Markel; Nivin Saleh; Gil Katz; Roi Gazit; Tsufit Gonen-Gross; Jacob Hanna; Efrat Nahari; Angel Porgador; Alik Honigman; Bodo Plachter; Dror Mevorach; Dana G Wolf; Ofer Mandelboim
Journal:  Nat Immunol       Date:  2005-04-10       Impact factor: 25.606

10.  Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.

Authors:  Y G Yang; B R Dey; J J Sergio; D A Pearson; M Sykes
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

View more
  43 in total

1.  NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation.

Authors:  Andreas T Björklund; Marie Schaffer; Cyril Fauriat; Olle Ringdén; Mats Remberger; Christina Hammarstedt; A John Barrett; Per Ljungman; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Blood       Date:  2010-01-22       Impact factor: 22.113

2.  Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.

Authors:  Charles Craddock; Sandeep Nagra; Andrew Peniket; Cassandra Brookes; Laura Buckley; Emmanouil Nikolousis; Nick Duncan; Sudhir Tauro; John Yin; Effie Liakopoulou; Panos Kottaridis; John Snowden; Donald Milligan; Gordon Cook; Eleni Tholouli; Tim Littlewood; Karl Peggs; Paresh Vyas; Fiona Clark; Mark Cook; Stephen Mackinnon; Nigel Russell
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

3.  Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection.

Authors:  Sandra Lopez-Vergès; Jeffrey M Milush; Brian S Schwartz; Marcelo J Pando; Jessica Jarjoura; Vanessa A York; Jeffrey P Houchins; Steve Miller; Sang-Mo Kang; Phillip J Norris; Douglas F Nixon; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

Review 4.  Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy.

Authors:  Piyanuch Kongtim; Dean A Lee; Laurence J N Cooper; Partow Kebriaei; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-11       Impact factor: 5.742

5.  Changes in natural killer cell subsets in pediatric liver transplant recipients.

Authors:  Betty Pham; Karine Piard-Ruster; Richard Silva; Amy Gallo; Carlos O Esquivel; Olivia M Martinez; Sheri M Krams
Journal:  Pediatr Transplant       Date:  2012-03

Review 6.  NFAT as cancer target: mission possible?

Authors:  Jiang-Jiang Qin; Subhasree Nag; Wei Wang; Jianwei Zhou; Wei-Dong Zhang; Hui Wang; Ruiwen Zhang
Journal:  Biochim Biophys Acta       Date:  2014-07-26

Review 7.  Biology and clinical effects of natural killer cells in allogeneic transplantation.

Authors:  Jonathan E Benjamin; Saar Gill; Robert S Negrin
Journal:  Curr Opin Oncol       Date:  2010-03       Impact factor: 3.645

8.  Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity.

Authors:  Diana Stauch; Annelie Dernier; Elizabeth Sarmiento Marchese; Kristina Kunert; Hans-Dieter Volk; Johann Pratschke; Katja Kotsch
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

9.  Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo.

Authors:  Olivier Morteau; Samkeliso Blundell; Aron Chakera; Sophia Bennett; Charita M Christou; Philip D Mason; Richard J Cornall; Christopher A O'Callaghan
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

Review 10.  Immunotherapy for pediatric cancer.

Authors:  Stephan A Grupp; Michael Verneris; Paul M Sondel; Laurence J N Cooper
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.